Business
Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd
Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd.
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"DENVER, CO / ACCESSWIRE / March 28, 2019 / Nexien BioPharma, Inc. ("Nexien" or the "Company") (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development, and commercialization of advanced FDA Compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that its management will present at The MicroCap Conference Spring Investor Summit in New York City on Tuesday, April 2, 2019.Alex Wasyl, Chief Executive Officer, is scheduled to present at 3:00 p.m. ET and will be available for one-on-one meetings with attendees throughout the day. A copy of the investor presentation will be available in the investor relations section of Nexien's website at https://nexienbiopharma.com/investors.CONFERENCE OVERVIEW AND STRUCTUREThe Spring Investor Summit (formerly The MicroCap Conference) is an exclusive event dedicated to connecting small and micro cap companies with high-level, institutional and retail investors. The Spring Investor Summit will take place in New York City at the Essex House on April 1st and 2nd. The upcoming conference will feature 200 presenting companies, 1200 institutional and retail investors, 2000 one-on-one meetings, expert speakers, and industry panels.REGISTRATION FOR INVESTORSTo request free registration, please go to our website (www.springinvestorsummit.com), and click the "Registration" buttonPARTICIPATING COMPANIESFor our most updated list of companies, please go to our website (www.springinvestorsummit.com)About Nexien BioPharma Inc.Nexien BioPharma is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid pharmaceuticals in accordance with U.S. Food and Drug Administration ("FDA") pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders. For more information, visit Nexien BioPharma's website at: www.nexienbiopharma.com.ContactsNexien BioPharma, [email protected] Equity GroupKalle Ahl, CFA(212) [email protected] Sullivan(212) [email protected] SOURCE: Nexien BioPharma, Inc. ","length":2707,"tagName":"div"}]